Small molecules alter VEGFR and PTEN expression in HPVpositive and-negative SCC: New hope for targeted-therapy

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1389-1400

  Aderhold, Christoph ^a   Faber, Anne ^a   Umbreit, Claudia ^a   Chakraborty, Anja ^a   Bockmayer, Andre ^a   Birk, Richard ^a   Sommer, Jörg Ulrich ^a   Hörmann, Karl ^a   Schultz, Johannes David ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Everolimus; Head and neck squamous cell carcinoma; PTEN; Sorafenib; Sunitinib; Tyrosine kinase inhibitor; VEGFR

Indexed keywords

EVEROLIMUS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; PTEN PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL LYSATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN PAPILLOMAVIRUS POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; TUMOR CELL LINE; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PAPILLOMAVIRIDAE; PTEN PHOSPHOHYDROLASE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84924943712     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN and Pickle LW: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427, 2005.
3. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O, Pilarska A, Zhang ZF, Ferro G, Berthiller J and Boffetta P: Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 18: 541-550, 2009.
4. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Koifman S, La Vecchia C, Lazarus P, Levi F, Mates D, Matos E, Menezes A, Muscat J, Eluf-Neto J, Olshan AF, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Zaridze D, Zatonski W, Zhang ZF, Berthiller J and Boffetta P: Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99: 777-789, 2007.
5. Gillison ML and Lowy DR: A causal role for human papillomavirus in head and neck cancer. Lancet 363: 1488-1489, 2004.
6. Sturgis EM and Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 110: 1429-1435, 2007.
7. Shiboski CH, Schmidt BL and Jordan RC: Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103: 1843-1849, 2005.
8. Chaturvedi AK, Engels EA, Anderson WF and Gillison ML: Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619, 2008.
9. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S and Viscidi R: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420, 2008.
10. Romanitan M, Nasman A, Ramqvist T, Dahlstrand H, Polykretis L, Vogiatzis P, Vamvakas P, Tasopoulos G, Valavanis C, Arapantoni-Dadioti P, Banis K and Dalianis T: Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 28: 2077-2080, 2008.
11. Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP and Haugen TH: Human papillomavirus and risk of oral cancer. Laryngoscope 108: 1098-1103, 1998.
12. Koch WM, Lango M, Sewell D, Zahurak M and Sidransky D: Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 109: 1544-1551, 1999.
13. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA and Grandis JR: The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160, 2011.
14. Le Buanec H, D'Anna R, Lachgar A, Zagury JF, Bernard J, Ittele D, d'Alessio P, Hallez S, Giannouli C, Burny A, Bizzini B, Gallo RC and Zagury D: HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother 53: 424-431, 1999.
15. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J and Kerbel RS: Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53-independent manner. Oncogene 19: 4611-4620, 2000.
16. Tang X, Zhang Q, Nishitani J, Brown J, Shi S and Le AD: Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13: 2568-2576, 2007.
17. Lindel K, Beer KT, Laissue J, Greiner RH and Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92: 805-813, 2001.
18. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A and Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008.
19. Park CC, Bissell MJ and Barcellos-Hoff MH: The influence of the microenvironment on the malignant phenotype. Mol Med Today 6: 324-329, 2000.
20. De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447, 2003.
21. Eisma RJ, Spiro JD and Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513-517, 1997.
22. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A and Wennerberg J: Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 83: 775-781, 2000.
23. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH and Rubin K: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934, 2001.
24. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M and Westermark B: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90: 393-397, 1993.
25. Nemunaitis J and Nemunaitis J: Head and neck cancer: response to p53-based therapeutics. Head Neck 33: 131-134, 2011.
26. Knudson AG, Jr.: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971.
27. Knudson AG, Jr., Hethcote HW and Brown BW: Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 72: 5116-5120, 1975.
28. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45: 324-334, 2009.
29. Liu W, Zhou Y, Reske SN and Shen C: PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 28: 3613-3619, 2008.
30. Henderson YC, Wang E and Clayman GL: Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. Laryngoscope 108: 1553-1556, 1998.
31. Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, Parsons R and Sato T: Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 77: 684-688, 1998.
32. Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, Hong WK and Mao L: Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127: 1441-1445, 2001.
33. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV and Kulkarni AB: Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31: 3322-3332, 2012.
34. Dunlop EA and Tee AR: Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal 21: 827-835, 2009.
35. Humar R, Kiefer FN, Berns H, Resink TJ and Battegay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16: 771-780, 2002.
36. Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4: 51, 2011.
37. Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ and Shun CT: Clinical experience of tacrolimus with everolimus in heart transplantation. Transplant Proc 44: 907-909, 2012.
38. Agarwala SS and Case S: Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15: 236-245, 2010.
39. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, 3rd, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Jr., Mortimer J, Reckamp K, Venook AP, Worden F and Yen Y: NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 6(Suppl 5): S1-20, 2008.
40. Nguyen SA, Walker D, Gillespie MB, Gutkind JS and Day TA: mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. Curr Treat Options Oncol 13: 71-81, 2012.
41. Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P and Milano G: The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 47: 340-344, 2011.
42. Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC and Milano G: Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 20: 1703-1707, 2009.
43. Fury MG, Sherman E, Haque S, Korte S, Lisa D, Shen R, Wu N and Pfister D: A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol 69: 591-598, 2012.
44. Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R, Molinolo AA and Gutkind JS: Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 71: 7103-7112, 2011.
45. Sawicki M, Szudy A, Szczyrek M, Krawczyk P and Klatka J: Molecularly targeted therapies in head and neck cancers. Otolaryngol Pol 66: 307-312, 2012.
46. Adjei AA, Blumenschein GR, Jr., Mandrekar S, Hillman S, Gatzemeier U and Heigener D: Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer 12: 212-217, 2011.
47. Du J, Qian X and Liu B: Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature. Oncol Lett 5: 381-385, 2013.
48. Egberts F, Gutzmer R, Ugurel S, Becker JC, Trefzer U, Degen A, Schenck F, Frey L, Wilhelm T, Hassel JC, Schadendorf D, Livingstone E, Mauch C, Garbe C, Berking C, Rass K, Mohr P, Kaehler KC, Weichenthal M and Hauschild A: Sorafenib and pegylated interferon-alpha2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 22: 1667-1674, 2011.
49. Ibrahim N, Yu Y, Walsh WR and Yang JL: Molecular targeted therapies for cancer: sorafenib monotherapy and its combination with other therapies (review). Oncol Rep 27: 1303-1311, 2012.
50. Dal Lago L, D'Hondt V and Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 13: 845-858, 2008.
51. Blumenschein GR, Jr., Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC and Juhasz E: Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol 7: 1406-1416, 2012.
52. Pasqualetti G, Ricci S, Dardano A, Ferdeghini M, Del Tacca M and Monzani F: The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature. Mini Rev Med Chem 11: 746-752, 2011.
53. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, 3rd, Ivy P, Karrison TG, Dekker A, Vokes EE and Cohen EE: Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 28: 677-683, 2010.
54. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, Andreiuolo F and Marselos M: A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 65: 649-660, 2010.
55. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T and Guigay J: Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 28: 21-28, 2010.
56. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O and Chen EX: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25: 3766-3773, 2007.
57. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT and Urba SG: Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 28: 3330-3335, 2010.
58. Fury MG, Sherman E, Ho AL, Xiao H, Tsai F, Nwankwo O, Sima C, Heguy A, Katabi N, Haque S and Pfister DG: A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 2013.
59. Riedel F, Gotte K, Schwalb J, Schafer C and Hormann K: Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol 120: 105-111, 2000.
60. Riedel F and Hormann K: Anti-angiogenesis-a therapy concept in the treatment of head and neck carcinomas? A review. Laryngorhinootologie 80: 535-541, 2001 (in German).
61. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB and Krishna MC: Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 71: 6350-6359, 2011.
62. Saito K, Matsumoto S, Yasui H, Devasahayam N, Subramanian S, Munasinghe JP, Patel V, Gutkind JS, Mitchell JB and Krishna MC: Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS One 7: e49456, 2012.
63. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P and O'Reilly T: mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15: 1612-1622, 2009.
64. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB and Grandis JR: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064-5073, 2006.
65. Morgillo F, Martinelli E, Troiani T, Orditura M, De Vita F and Ciardiello F: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS One 6: e28841, 2011.
66. Adnane L, Trail PA, Taylor I and Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612, 2006.
67. Aderhold C, Faber A, Grobschmidt GM, Chakraborty A, Bockmayer A, Umbreit C, Birk R, Stern-Straeter J, Hormann K and Schultz JD: Small Molecule-based Chemotherapeutic Approach in p16-positive and-negative HNSCC in vitro. Anticancer Res 33: 5385-5393, 2013.
68. Abouantoun TJ, Castellino RC and MacDonald TJ: Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol 101: 215-226, 2011.
69. Ruan ZP, Xu R, Lv Y, Tian T, Wang WJ, Guo H and Nan KJ: PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res 20: 113-121, 2012.
70. Yang J, Ikezoe T, Nishioka C, Takezaki Y, Hanazaki K, Taguchi T and Yokoyama A: Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer 130: 959-966, 2012.
71. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP and Feron O: PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/AKT activation. Br J Cancer 109: 1586-1592, 2013.
72. Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD and Sarkaria JN: PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14: 3993-4001, 2008.
73. Arnedos M, Vielh P, Soria JC and Andre F: The genetic complexity of common cancers and the promise of personalized medicine: Is there any hope? J Pathol 232: 274-282, 2014.
74. Lito P, Rosen N and Solit DB: Tumor adaptation and resistance to RAF inhibitors. Nat Med 19: 1401-1409, 2013.